First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
2024 full-year revenue guidance raised by US$ 2 billion
Keimed is a leading wholesale pharma distribution with industry leading operating metrics
New solvent-free micronization technology expanded at the Darmstadt site in Germany
If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the EU
Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
Subscribe To Our Newsletter & Stay Updated
